Core Insights - Cognition Therapeutics, Inc. announced topline results from the SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies, which will be presented at the International Lewy Body Dementia Conference [1][2] - The study demonstrated significant efficacy signals, with zervimesine-treated participants showing improvements across various symptoms compared to placebo [2][5] Study Overview - The SHIMMER study was a Phase 2 clinical trial involving 130 adults with mild-to-moderate dementia with Lewy bodies, randomized to receive either zervimesine or placebo for six months [8][9] - The study met its primary endpoint of safety and tolerability, with most treatment-related adverse events being mild or moderate [4][5] Efficacy Results - Zervimesine-treated participants scored an average of 86% better on the neuropsychiatric inventory (NPI) A-L compared to placebo [2][5] - Participants on zervimesine preserved 52% more ability in activities of daily living (ADCS-ADL) and showed a 91% reduction in cognitive fluctuations [3][5] - Improvements in motor function were also noted, with zervimesine-treated patients maintaining 62% better motor function than those on placebo [3][5] Implications for Patients - The positive outcomes suggest that zervimesine may allow patients with dementia with Lewy bodies to live at home longer with the support of caregivers, reducing the need for care facility placement [4][5] - The study highlights the potential for zervimesine to alleviate debilitating neuropsychiatric and motor symptoms associated with the disease [2][4] Company Background - Cognition Therapeutics is focused on developing innovative therapeutics for age-related degenerative disorders, with zervimesine being a lead candidate currently investigated in clinical programs for dementia with Lewy bodies and Alzheimer's disease [11]
Cognition's Positive Phase 2 'SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC